Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Media outlets focus on audiences towards Alzheimer's disease: Intellect Neurosciences

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease, today announced that it is pleased with the recent press coverage the Company and Dr. Daniel G. Chain, Ph.D., the Company's Chairman and Chief Executive Officer, recently has received.

14 Jul 2010

Scientists discover three human antibodies that neutralize HIV

Scientists have discovered three previously unknown human antibodies that neutralize HIV, two of which target a broad range of HIV strains. The findings, reported online July 8 in two Science papers, add a level of encouragement to the AIDS vaccine research field.

14 Jul 2010

Researcher to lead $14.5M project to fight malaria in Southeast Asia

A researcher in Penn State's College of Agricultural Sciences will lead a seven-year, $14.5 million project to fight malaria in Southeast Asia. Liwang Cui, professor of entomology, is the principal investigator for the Southeast Asia Malaria Research Center, one of 10 International Centers of Excellence for Malaria Research announced by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

14 Jul 2010

Human Genome Sciences, Lonza announce commercial supply agreement for BENLYSTA

Human Genome Sciences, Inc. and Lonza today announced an agreement for the future commercial supply of BENLYSTA® (belimumab), which is currently under regulatory review in the United States and Europe as a potential new treatment for systemic lupus erythematosus (SLE). BENLYSTA is being developed by HGS and GlaxoSmithKline (GSK) under a co-development and commercialization agreement entered into in 2006.

13 Jul 2010

Irvine Scientific opens new Industrial Cell Culture media production facility in Tokyo, Japan

Irvine Scientific, a member of JX Holdings group, announced today the opening of a new Industrial Cell Culture media production facility in Tokyo, Japan. The new facility, located in Saitama prefecture, will manufacture the Company's cell culture media for production of biopharmaceuticals, vaccines, monoclonal antibodies and other media's used in pharmaceuticals, medicines, and research. The facility is being commissioned and validated as completely animal component free manufacturing facility.

12 Jul 2010

Phase II trial results of TB-402 presented at International Congress on Thrombosis

BioInvent International AB and ThromboGenics NV announce that the positive results from a Phase II trial of TB-402 (Anti-Factor VIII antibody) were presented at the 21st International Congress on Thrombosis in Milan, Italy yesterday. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism following orthopaedic surgery.

9 Jul 2010

UKPTO grants arGEN-X patent covering SIMPLE Antibody platform

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies using its proprietary SIMPLE Antibody(TM) platform, announces that it has been granted the first patent covering the platform. The patent GB2461546B, has been granted by the UK Patent and Trademark Office (UKPTO).

9 Jul 2010

PharmAthene reports progress in lyophilized rPA anthrax vaccine development program

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it continues to make solid progress in its lyophilized recombinant Protective Antigen (rPA) anthrax vaccine development program. The Company has recently demonstrated that its lyophilized rPA vaccine candidate is structurally stable and potent at various temperatures up to and including 70 degrees centigrade.

9 Jul 2010

Millipore launches new ProRes-S media for downstream purification of monoclonal antibodies, proteins

Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced the launch of its new ProRes-S media. With the addition of ProRes-S media, Millipore's purification suite now provides a complete solution for the downstream purification of monoclonal antibodies and proteins. Developed jointly with The Dow Chemical Company, ProRes-S media offers biopharmaceutical manufacturers greater flexibility and increased throughput in a smaller manufacturing footprint.

8 Jul 2010

Combination of Biothera's Imprime PGG and Erbitux doubles response rate in colorectal cancer patients

The combination of Biothera's experimental drug Imprime PGG® and Erbitux® (cetuximab) doubled the historical overall response rate and the time to progression of second- and third-line metastatic colorectal cancer patients treated with Erbitux monotherapy. The data was released last weekend at the 13th World Congress on Gastrointestinal Cancer at the European Society for Medical Oncology (ESMO).

7 Jul 2010

Initial Phase II study results of ofatumumab in patients with RRMS announced

Genmab A/S announced today positive interim results from an ofatumumab Phase II safety and pharmacokinetics study in patients with relapsing-remitting multiple sclerosis.

7 Jul 2010

Cornerstone reacquires all development, commercial rights to HMGB1 related technology from MedImmune

Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that the Company has reacquired all development and commercial rights to its high-mobility group box protein 1 (HMGB1) related technology from MedImmune, LLC.

6 Jul 2010

Neogenix Oncology files patent application with USPTO for 16C3 antigen

Neogenix Oncology announced today that the company has filed a patent application with the U.S. Patent and Trade Office (USPTO) for the 16C3 antigen. The Company believes that this antigen is tumor specific for pancreatic and colorectal tumors; and, based on preliminary clinical data, may also have diagnostic utility as a biomarker for these cancers.

3 Jul 2010

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has revealed new results from a global survey demonstrating that 66% of patients with metastatic colorectal cancer (mCRC) are now tested for KRAS to determine if they could benefit from a personalized therapy, such as Erbitux® (cetuximab). This represents a 50% increase in levels of KRAS testing in just one year.

1 Jul 2010

Highly specific assay developed to detect ERG alterations in prostate cancer

Researchers at the Uniformed Services University of the Health Sciences Center for Prostate Disease Research, in collaboration with investigators at the Armed Forces Institute of Pathology and Walter Reed Army Medical Center, have developed a highly specific assay for the detection of ERG, a protein associated with tumor formations which is present in more than half of all prostate cancers.

1 Jul 2010

Pre-clinical data of BiTE antibody technology published in PNAS

Micromet, Inc., today announced the publication of pre-clinical data in the Proceedings of the National Academy of Sciences, demonstrating the potency of new product candidates based on the Company's proprietary BiTE antibody technology. BiTE antibodies are a new class of agents designed to harness a patient's T cells to kill cancer cells.

1 Jul 2010

XOMA reaches enrollment goal of 325 patients for Phase 2b clinical trial of XOMA 052

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that it has reached the enrollment goal of 325 patients for its Phase 2b dose-ranging clinical trial of XOMA 052, and that it expects patient enrollment to close in July 2010, with top-line results available in the first quarter of 2011. XOMA 052 is a therapeutic antibody candidate that inhibits the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) which drives the inflammatory cause of Type 2 diabetes.

1 Jul 2010

USPTO issues Notice of Allowance for patent application related to Neogenix Oncology's 16C3 antibody

Neogenix Oncology announced today that the U.S. Patent and Trade Mark Office has issued a Notice of Allowance for a patent application related to its 16C3 antibody. Discovered and developed by Neogenix Oncology, this antibody appears to have anti-tumor activity for both pancreatic and colorectal tumors, and may have both therapeutic and diagnostic utility. The antibody may have activity in other tumors as well, which the company will explore at such time as it prepares a pre-IND package for FDA review and designs a clinical trial for the 16C3 antibody.

1 Jul 2010

AdVnt launches 15 Minute Black Mold Detection Test

AdVnt Biotechnologies, the company known for producing BioWarfare Agent Detection Devices for HAZMAT First Response Teams around the globe to help them rapidly detect such biological agents as Anthrax, Ricin and Botulinum, has just released its newest product for In-Home and Professional use. Building on the expertise gained in the international arena of BioWarfare Agent Detection, AdVnt is now applying its R&D expertise to help defend against another type of bio threat that could be growing in the walls and under the floorboards in your own home.

30 Jun 2010

Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

Keryx Biopharmaceuticals, Inc. today announced that abstract O-0017, entitled "Subset Analysis of 5-FU Refractory Patients from a Randomized Ph II Study of Perifosine + Capecitabine (P-CAP) vs. Placebo + Capecitabine (CAP) in Patients with 2nd or 3rd Line Metastatic CRC" has been selected for oral presentation at the upcoming 12th World Congress on Gastrointestinal Cancer, to be held in Barcelona, Spain from June 30 - July 2, 2010.

30 Jun 2010

Monoclonal Antibody News and Research

Further Reading

Media outlets focus on audiences towards Alzheimer's disease: Intellect Neurosciences

Scientists discover three human antibodies that neutralize HIV

Researcher to lead $14.5M project to fight malaria in Southeast Asia

Human Genome Sciences, Lonza announce commercial supply agreement for BENLYSTA

Irvine Scientific opens new Industrial Cell Culture media production facility in Tokyo, Japan

Phase II trial results of TB-402 presented at International Congress on Thrombosis

UKPTO grants arGEN-X patent covering SIMPLE Antibody platform

PharmAthene reports progress in lyophilized rPA anthrax vaccine development program

Millipore launches new ProRes-S media for downstream purification of monoclonal antibodies, proteins

Combination of Biothera's Imprime PGG and Erbitux doubles response rate in colorectal cancer patients

Initial Phase II study results of ofatumumab in patients with RRMS announced

Cornerstone reacquires all development, commercial rights to HMGB1 related technology from MedImmune

Neogenix Oncology files patent application with USPTO for 16C3 antigen

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

Highly specific assay developed to detect ERG alterations in prostate cancer

Pre-clinical data of BiTE antibody technology published in PNAS

XOMA reaches enrollment goal of 325 patients for Phase 2b clinical trial of XOMA 052

USPTO issues Notice of Allowance for patent application related to Neogenix Oncology's 16C3 antibody

AdVnt launches 15 Minute Black Mold Detection Test

Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

Immunology eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News